JBTM Stock Analysis: JBTMarel | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 5.634m USD | 12M Return: -27.1% | US4778391049 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 60.2M
EPS Trend: -10.6%
Qual. Beats: 0
Rev. Trend: 91.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
JBT Marel Corporation is a Chicago-headquartered provider of technology, equipment, software, and services for the global food and beverage processing industry. It operates through two segments - Protein Solutions and Prepared Food and Beverage Solutions - covering the full processing value chain from stunning, slaughtering, and chilling through mixing, forming, cooking, freezing, pasteurizing, packaging, and end-of-line material handling. Its customer base spans poultry, beef, pork, seafood, dairy, bakery, ready-to-eat meals, pet food, plant-based alternatives, beverages, and aqua feed producers across the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Beyond core food processing, the company also supplies automated guided vehicle (AGV) systems for material handling in automotive manufacturing, warehouse, and medical facilities, giving it a modest diversification angle outside its primary protein-and-food end markets. Sales and service are delivered through direct sales teams, independent distributors, sales representatives, and technical service groups. Classified within the Industrials sector (Industrial Machinery & Supplies & Components), JBT Marel was incorporated in 1994 and assumed its current name in January 2025 following its earlier identity as John Bean Technologies Corporation.
- Protein processing equipment demand tied to global poultry and beef capex cycles
- Marel merger integration drives cost synergies and margin expansion
- Food safety regulations boost demand for automated processing and packaging solutions
| Net Income: 192.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.48 > 1.0 |
| NWC/Revenue: 7.92% < 20% (prev -4.23%; Δ 12.15% < -1%) |
| CFO/TA 0.05 > 3% & CFO 426.1m > Net Income 192.1m |
| Net Debt (1.57b) to EBITDA (544.2m): 2.88 < 3 |
| Current Ratio: 1.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.2m) vs 12m ago 0.0% < -2% |
| Gross Margin: 35.55% > 18% (prev 35.78%; Δ -0.23% > 0.5%) |
| Asset Turnover: 48.30% > 50% (prev 32.84%; Δ 15.46% > 0%) |
| Interest Coverage Ratio: 5.23 > 6 (EBIT TTM 294.2m / Interest Expense TTM 56.3m) |
| A: 0.04 (Total Current Assets 1.61b - Total Current Liabilities 1.30b) / Total Assets 8.01b |
| B: 0.19 (Retained Earnings 1.53b / Total Assets 8.01b) |
| C: 0.04 (EBIT TTM 294.2m / Avg Total Assets 8.13b) |
| D: 1.27 (Book Value of Equity 4.47b / Total Liabilities 3.53b) |
| Altman-Z'' = 2.45 = A |
| DSRI: 0.75 (Receivables 587.0m/542.2m, Revenue 3.93b/2.71b) |
| GMI: 1.01 (GM 35.78% / 35.55%) |
| AQI: 0.98 (AQ_t 0.70 / AQ_t-1 0.72) |
| SGI: 1.45 (Revenue 3.93b / 2.71b) |
| TATA: -0.03 (NI 192.1m - CFO 426.1m) / TA 8.01b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at USD 105.36 with a total of 583,580 shares traded. Over the past week, the price has changed by -1.40%, over one month by -9.14%, over three months by -24.09% and over the past year by -27.13%.
Current recommended Stop Loss: 101.00 (which is 4.1% or 1.3 ATR below the current price).
JBTMarel has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy JBTM.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 167.1 | 58.6% |
P/E Trailing = 28.8064
P/E Forward = 12.2249
P/S = 1.4349
P/B = 1.3141
P/EG = 1.2201
Revenue TTM = 3.93b USD
EBIT TTM = 294.2m USD
EBITDA TTM = 544.2m USD
Long Term Debt = 1.67b USD (from longTermDebt, last quarter)
Short Term Debt = 9.00m USD (from shortTermDebt, last quarter)
Debt = 1.68b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.57b USD (calculated: Debt 1.68b - CCE 112.0m)
Enterprise Value = 7.20b USD (5.63b + Debt 1.68b - CCE 112.0m)
Interest Coverage Ratio = 5.23 (Ebit TTM 294.2m / Interest Expense TTM 56.3m)
EV/FCF = 23.23x (Enterprise Value 7.20b / FCF TTM 310.0m)
FCF Yield = 4.31% (FCF TTM 310.0m / Enterprise Value 7.20b)
FCF Margin = 7.90% (FCF TTM 310.0m / Revenue TTM 3.93b)
Net Margin = 4.89% (Net Income TTM 192.1m / Revenue TTM 3.93b)
Gross Margin = 35.55% ((Revenue TTM 3.93b - Cost of Revenue TTM 2.53b) / Revenue TTM)
Gross Margin QoQ = 36.60% (prev 35.15%)
Tobins Q-Ratio = 0.90 (Enterprise Value 7.20b / Total Assets 8.01b)
Interest Expense / Debt = 3.35% (Interest Expense 56.3m / Debt 1.68b)
Taxrate = 18.92% (45.0m / 237.9m)
NOPAT = 238.6m (EBIT 294.2m * (1 - 18.92%))
Current Ratio = 1.24 (Total Current Assets 1.61b / Total Current Liabilities 1.30b)
Debt / Equity = 0.38 (Debt 1.68b / totalStockholderEquity, last quarter 4.47b)
Debt / EBITDA = 2.88 (Net Debt 1.57b / EBITDA 544.2m)
Debt / FCF = 5.05 (Net Debt 1.57b / FCF TTM 310.0m)
Total Stockholder Equity = 4.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.36% (Net Income 192.1m / Total Assets 8.01b)
RoE = 4.31% (Net Income TTM 192.1m / Total Stockholder Equity 4.46b)
RoCE = 4.80% (EBIT 294.2m / Capital Employed (Equity 4.46b + L.T.Debt 1.67b))
RoIC = 3.61% (NOPAT 238.6m / Invested Capital 6.60b)
WACC = 7.74% (E(5.63b)/V(7.31b) * Re(9.23%) + D(1.68b)/V(7.31b) * Rd(3.35%) * (1-Tc(0.19)))
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.82 | Cagr: 23.95%
[DCF] Terminal Value 76.74% ; FCFF base≈298.0m ; Y1≈325.7m ; Y5≈408.5m
[DCF] Fair Price = 90.20 (EV 6.25b - Net Debt 1.57b = Equity 4.68b / Shares 51.9m; r=8.35% [WACC [floored]]; 5y FCF grow 10.67% → 2.50% )
EPS Correlation: -10.57 | EPS CAGR: -7.60% | SUE: -0.05 | # QB: 0
Revenue Correlation: 91.44 | Revenue CAGR: 45.71% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.10 | Chg30d=-0.57% | Revisions=-25% | Analysts=8
EPS current Year (2026-12-31): EPS=8.03 | Chg30d=-0.31% | Revisions=-25% | GrowthEPS=+25.3% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=9.23 | Chg30d=-0.39% | Revisions=-25% | GrowthEPS=+14.9% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: -50% (up=0, down=3)